Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study Kim, Y. H., Whittaker, S., Horwitz, S. M., Duvic, M., Dummer, R., Scarisbrick, J. J., Quaglino, P., Zinzani, P., Wolter, P., Wang, Y., Palanca-Wessels, M., Zagadailov, E., Trepicchio, W. L., Liu, Y., Little, M., Prince, H. AMER SOC HEMATOLOGY. 2016
View details for Web of Science ID 000394446803146